Variation of serum erythropoietin ( EPO, a), soluble transferrin receptors ( sTfR, b) and ferritin ( Ferritin, c)

Richalet J-P,Rivera M,Maignan M,Pham I,Privat C,Leon-Velarde F.Pulmonary hypertension and monges disease. [Internet]. 2009 ;1:114. Available from:http://www.pvrireview.org/text.asp?2009/1/2/114/50730

Variation of serum erythropoietin ( EPO, a), soluble transferrin receptors ( sTfR, b) and ferritin ( Ferritin, c), after treatment by 250 mg (D250) or 500 mg (D500) of ACZ compared to CMS placebo-treated group (Placebo) and normal control subjects (Control). Data are mean SD. *, **, ***, P < 0.05, P < 0.01 and P < 0.001 after versus before treatment. #, ###, P < 0.05 and P < 0.001 versus Placebo.

Additional keywords: EPO,chronic mountain sickness,ferritin

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Related Content

{{GlobalController.truncateTitle("Cardiac output and maximal tricuspid regurgitation pressure (as an index of systolic pulmonary artery pressure) in three groups of subjects", 65)}}

{{GlobalController.truncateTitle("Relationship between pulmonary artery pressure and arterial oxygen saturation in CMS patients and healthy highlanders", 65)}}

{{GlobalController.truncateTitle("Effect of 3- and 6-month treatment with either acetazolamide (ACZ) or placebo on pulmonary vascular resistance and pulmonary acceleration time in CMS patients", 65)}}

{{GlobalController.truncateTitle("Arterial oxygen saturation (SaO2) and hematocrit in three groups of subjects", 65)}}

{{GlobalController.truncateTitle("Hematopoietic stem cell hierarchy", 65)}}

Add to reading list

Share this content

Our research platform is the world.